Tropical Cyclone Storm Surge Detection in Slash Pine Radial Growth along the Northern Gulf of Mexico Coastline

My thesis examines the ecological impact of tropical cyclone (TCs) storm surge on coastal slash pine (Pinus elliottii var. elliottii Engelm) communities along the Gulf of Mexico in the southern United States (U.S.). Previous research has shown slash pine radial growth trends can be examined to identify long and short-term growth changes associated with TC passage, providing insight into overall stand health and resiliency through time. However, this previous research encompasses just one site in Mississippi. My thesis expands the spatial footprint of TC-surge impact on slash pine radial growth with the addition of three new sites. I examined seasonally resolved tree-ring data from two sites in Alabama and one in Florida and discovered differences in geography and seasonality to suppressions and recovery. The Weeks Bay, Fairhope, Alabama site was the most responsive to storm-surge suppressions, and this was perhaps due to lack of dune protection and proximity to a concave coastline. Latewood growth recorded the highest percentage of suppressions associated with storm surge and was generally the quickest growth metric to recover to normal growing conditions. TCs are predicted to become larger and more powerful in the 21st century, and it will be necessary to consider the negative impacts that these storms can have on coastal pine savannas while constructing plans to protect and preserve these unique environments

Latewood Ring Width Reveals CE 1734 Felling Dates for Walker House Timbers In Tupelo, Mississippi, USA

Dendroarchaeology is under-represented in the Gulf Coastal Plain region of the United States (US), and at present, only three published studies have precision dated a collection of 18th–19th-century structures. In this study, we examined the tree-ring data from pine, poplar, and oak timbers used in the Walker House in Tupelo, Mississippi. The Walker House was constructed ca. the mid-1800s with timbers that appeared to be recycled from previous structures. In total, we examined 30 samples (16 pines, 8 oaks, and 6 poplars) from the attic and crawlspace. We cross-dated latewood ring growth from the attic pine samples to the period 1541–1734 (r = 0.52, t = 8.43, p \u3c 0.0001) using a 514-year longleaf pine (Pinus palustris Mill.) latewood reference chronology from southern Mississippi. The crawlspace oak samples produced a 57-year chronology that we dated against a white oak (Quercus alba L.) reference chronology from northeast Alabama to the period 1765–1822 (r = 0.36, t = 2.83, p \u3c 0.01). We were unable to cross-date the six poplar samples due to a lack of poplar reference chronologies in the region. Our findings have two important implications: (1) the pine material dated to 1734 represents the oldest dendroarchaeology-confirmed dating match for construction materials in the southeastern US, and (2) cross-dating latewood growth for southeastern US pine species produced statistically significant results, whereas total ring width failed to produce significant dating results

Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder leading to muscle weakness and respiratory failure. Arimoclomol, a heat-shock protein-70 (HSP70) co-inducer, is neuroprotective in animal models of amyotrophic lateral sclerosis, with multiple mechanisms of action, including clearance of protein aggregates, a pathological hallmark of sporadic and familial amyotrophic lateral sclerosis. We aimed to evaluate the safety and efficacy of arimoclomol in patients with amyotrophic lateral sclerosis. ORARIALS-01 was a multinational, randomised, double-blind, placebo-controlled, parallel-group trial done at 29 centres in 12 countries in Europe and North America. Patients were eligible if they were aged 18 years or older and met El Escorial criteria for clinically possible, probable, probable laboratory-supported, definite, or familial amyotrophic lateral sclerosis; had an ALS Functional Rating Scale-Revised score of 35 or more; and had slow vital capacity at 70% or more of the value predicted on the basis of the participant's age, height, and sex. Patients were randomly assigned (2:1) in blocks of 6, stratified by use of a stable dose of riluzole or no riluzole use, to receive oral arimoclomol citrate 1200 mg/day (400 mg three times per day) or placebo. The Randomisation sequence was computer generated centrally. Investigators, study personnel, and study participants were masked to treatment allocation. The primary outcome was the Combined Assessment of Function and Survival (CAFS) rank score over 76 weeks of treatment. The primary outcome and safety were analysed in the modified intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03491462, and is completed. Between July 31, 2018, and July 17, 2019, 287 patients were screened, 245 of whom were enrolled in the trial and randomly assigned. The modified intention-to-treat population comprised 239 patients (160 in the arimoclomol group and 79 in the placebo group): 151 (63%) were male and 88 (37%) were female; mean age was 57·6 years (SD 10·9). CAFS score over 76 weeks did not differ between groups (mean 0·51 [SD 0·29] in the arimoclomol group vs 0·49 [0·28] in the placebo group; p=0·62). Cliff's delta comparing the two groups was 0·039 (95% CI –0·116 to 0·194). Proportions of participants who died were similar between the treatment groups: 29 (18%) of 160 patients in the arimoclomol group and 18 (23%) of 79 patients in the placebo group. Most deaths were due to disease progression. The most common adverse events were gastrointestinal. Adverse events were more often deemed treatment-related in the arimoclomol group (104 [65%]) than in the placebo group (41 [52%]) and more often led to treatment discontinuation in the arimoclomol group (26 [16%]) than in the placebo group (four [5%]). Arimoclomol did not improve efficacy outcomes compared with placebo. Although available biomarker data are insufficient to preclude future strategies that target the HSP response, safety data suggest that a higher dose of arimoclomol would not have been tolerated. Orphazyme